A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

Inclusion Criteria:

Inclusion criteria for long-term follow-up (LTFU) study participants only

• Study participants ≥ 1 month of age with a confirmed diagnosis of epilepsy whoparticipated in core study N01266 [NCT01364597] and/or N01349 [NCT03325439]

Inclusion criteria for directly enrolled (DE) study participants in Japan only

• Study participant is ≥ 4 years to < 16 years of age

• Study participant has presence of an electroencephalogram (EEG) reading compatiblewith the diagnosis of focal epilepsy within the last 10 years

• Study participant has uncontrolled partial-onset seizure (POS) after an adequatecourse of treatment with at least 1 antiepileptic drug (AED)

• Study participant had at least 1 POS during the 4-week Screening Period

Exclusion Criteria:

Exclusion criteria for all study participants

• Severe medical, neurological, or psychiatric disorders or laboratory values, whichmay have an impact on the safety of the study participant

• Study participant is currently participating in another study of an investigationalmedication (or a medical device) other than brivaracetam (BRV).

Exclusion criteria for long-term follow-up (LTFU) study participants only

• Study participant ≥ 6 years of age has a lifetime history of suicide attempt or hassuicidal ideation in the past 6 months as indicated on the Columbia Suicide SeverityRating Scale (C-SSRS)

Exclusion criteria for directly enrolled (DE) study participants in Japan only

• Study participant has a history of primary generalized epilepsy, psychogenicnon-epileptic seizures, or febrile seizures

• Study participant has a history of status epilepticus in the 30 days prior to theScreening Visit (ScrV) or during the Screening Period

• Study participant has any clinically significant illness

• Study participant has clinically significant laboratory abnormality that mayincrease the risk associated with study participation or may interfere with theinterpretation of study results

• Study participant has a clinically significant ECG abnormality

• Study participant had major surgery within 6 months prior to the ScrV